Growth Metrics

Iradimed (IRMD) Depreciation & Amortization (CF) (2016 - 2026)

Iradimed has reported Depreciation & Amortization (CF) over the past 14 years, most recently at $455000.0 for Q1 2026.

  • Quarterly Depreciation & Amortization (CF) rose 134.54% to $455000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Mar 2026, up 81.57% year-over-year, with the annual reading at $1.2 million for FY2025, 42.54% up from the prior year.
  • Depreciation & Amortization (CF) was $455000.0 for Q1 2026 at Iradimed, up from $380680.0 in the prior quarter.
  • Over five years, Depreciation & Amortization (CF) peaked at $494176.0 in Q2 2022 and troughed at -$692905.0 in Q4 2022.
  • The 5-year median for Depreciation & Amortization (CF) is $205375.0 (2023), against an average of $227932.5.
  • Year-over-year, Depreciation & Amortization (CF) plummeted 279.23% in 2022 and then surged 134.54% in 2026.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at -$692905.0 in 2022, then surged by 129.64% to $205375.0 in 2023, then fell by 4.95% to $195210.0 in 2024, then surged by 95.01% to $380680.0 in 2025, then grew by 19.52% to $455000.0 in 2026.
  • Per Business Quant, the three most recent readings for IRMD's Depreciation & Amortization (CF) are $455000.0 (Q1 2026), $380680.0 (Q4 2025), and $383722.0 (Q3 2025).